IBM Watson癌症治疗应用在美首次渗透社区医院

2017-02-08 廖青 健康点

位于佛罗里达州的朱庇特医疗中心是一个非营利性社区医疗中心,拥有327张床位。该中心近日对外表示,计划引进IBM的认知计算系统——IBM Watson (以下简称Watson)来进行肿瘤治疗。朱庇特医疗中心是美国第一家采用Watson技术的区域性医院,目标定位在帮助医生实施个性化、循证的癌症治疗。AI癌症治疗首次应用于社区医院据美国癌症协会预测,美国今年将新增170万癌症病例。单

位于佛罗里达州的朱庇特医疗中心是一个非营利性社区医疗中心,拥有327张床位。该中心近日对外表示,计划引进IBM的认知计算系统——IBM Watson (以下简称Watson)来进行肿瘤治疗。朱庇特医疗中心是美国第一家采用Watson技术的区域性医院,目标定位在帮助医生实施个性化、循证的癌症治疗

AI癌症治疗首次应用于社区医院

据美国癌症协会预测,美国今年将新增170万癌症病例。单单在佛罗里达州,这一数字将达12.5万人。肿瘤治疗中的Watson旨在帮助爆炸式增长的癌症患者人群。

Watson的人工智能技术可以提高肿瘤医生评估医学文献,快速抓住病历内容,还有助于提供给肿瘤医生循证的治疗选项。Watson截至目前学习了300多本期刊,200多本教材,将近1500万页的文献,来为医生针对不同诊疗方法、药品和实践提供建议。Watson还根据疗效给建议分级,用以配合“同行评审”的研究和临床试验。

“在朱庇特医疗中心,我们致力于探索药学和保健领域中的新方法。”朱庇特医疗中心的主席兼CEO John D. Couris说:“肿瘤治疗中的Watson构成我们世界级癌症研究项目中的一部分。我们非常荣幸能够成为美国第一家采用这么先进技术的社区医院。”

IBM Watson Health肿瘤与基因组研究中心的副主席Rob Merkel认为“全球和全美的社区越来越需要提高效率以及从浩如烟海的癌症研究中快速获取重要信息的办法。”

“我们为Watson非凡的推理、提供治疗建议的能力所震惊。这一能力使医生可以为病人量身定制个性化的疗程。” 朱庇特医疗中心的总经理,肿瘤治疗负责人Abraham Schwarzberg说。不仅如此,Watson还能帮助朱庇特医疗中心致力于肿瘤治疗的跨学科团队厘清个人贡献。

Watson在全球领域的癌症应用

Watson在癌症领域的应用已经从美国本土逐渐覆盖到全球多个国家。

从技术发展而言,美国顶级的肿瘤中心MSK(Memorial Sloan Kettering Cancer Center)已全面使用Watson作为辅助手段来分析患者的个人病情、诊断结果等。 IBM和MSK在推动训练肿瘤治疗中的Watson,以用来为临床医生提供乳腺癌、肺癌、直肠癌、宫颈癌、卵巢癌胃癌治疗方案。2017年,Watson还将拓展至另外九种癌症,覆盖全球80%的癌症病例。

在美国北卡罗来纳大学,Lineberger癌症综合中心的研究人员也正与Watson合作,帮助癌症晚期患者选择更具疗效的全新治疗方案。通过分析复杂的基因数据和最新的研究成果,Watson帮助医生发现原本可能失之交臂的治疗方案。

美国以外,IBM Watson与东京大学医学院合作,在治疗白血病方面颇有建树。Watson在10分钟内阅读和分析了2000万份医学文献、论文和病理,帮助该医学院收治的一位66岁女性白血病患者寻找其基因突变点,并找到了有效的治疗方案。目前,这位病人正在康复中。在澳大利亚,IBM与Melanoma Institute Australia开展科研项目,利用AI技术提升对黑色素瘤的识别。

此外,IBM与数家知名药企如辉瑞、阿斯利康也开展了在肿瘤领域的合作。例如,辉瑞的肿瘤研究院使用Watson for Drug Discovery来分析大量不同的数据源,发现新的药物靶标和替代药物的适应症。Watson for Drug Discovery已经摄取了2500万份Medline摘要、超过100万篇医学期刊文章全文、400万篇专利文章。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-24 Dr.Q

    不错,收藏了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-10 tulenzi
  7. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 Dr.Q

    非常有用,受益

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 wmu姿

    相互交流,谢谢

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 xiaotaiyang1

    看看

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2068225, encodeId=ba0420682256d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sat Jun 17 05:23:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844202, encodeId=427c184420299, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat May 06 20:23:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991385, encodeId=50121991385fc, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Mon May 08 07:23:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177756, encodeId=d3331e7756ec, content=不错,收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Fri Feb 24 16:05:51 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395655, encodeId=e5b0139565538, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489930, encodeId=2365148993002, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Fri Feb 10 00:23:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174933, encodeId=51dc1e4933dc, content=非常有用,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e581988587, createdName=Dr.Q, createdTime=Wed Feb 08 11:05:50 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174922, encodeId=72d11e4922ad, content=相互交流,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Wed Feb 08 10:15:36 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174921, encodeId=791f1e492169, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Feb 08 09:57:29 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=174918, encodeId=bd091e491886, content=精彩, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150714/IMG55A4FADCE0F987688.jpg, createdBy=23af1632396, createdName=1dd8f26bm82(暂无匿称), createdTime=Wed Feb 08 09:47:12 CST 2017, time=2017-02-08, status=1, ipAttribution=)]
    2017-02-08 1dd8f26bm82(暂无匿称)

    精彩

    0

相关资讯

IBM智慧医疗推动助力上海医疗业应对大数据挑战

12月5日,由IBM、上海市卫生局信息中心、中国数字医疗网联合举办的上海市公立医院改革研讨会在 上海召开。本次研讨会围绕上海公立医院改革新举措、上海市电子病例等级评审、大数据推动新医改等相关热点话题展开,旨在更好地落实《中共中央国务院关于深 化医药卫生体制改革的意见》精神,进一步推进卫生统计与信息化建设工作进程,促进上海市公立医院改革发展进程,提升卫生统计及信息化工作服务能力。 大数据时

IBM:预测未来5年科技动向,包括更智慧的医疗和更智慧的教室

IBM 刚刚公布了最新的未来 5 年 5 大预测。这些预测是通过对 22 万技术从业者的调查后,由 IBM 的众多实验室通力分析得出的结论。凡事预则立,最近 8 年,IBM 每年都要进行这样的预测—以便于该公司集中研发火力。 概而言之,IBM 的这 5 项预测是: —更智慧的教室 —更智慧的商店 —更智慧的医疗 —更智慧的安全 —更智慧的城市

IBM在2014年将推出个性化医疗服务的三款超级计算机

    据Business Insider网站报道,IBM表示,明年其商业合作伙伴将发布三款基于IBM超级计算机Watson的应用软件。     IBM Watson解决方案高级副总裁斯蒂芬•登(Stephen Gold)表示,明年,消费者将见到由IBM商业合作伙伴开发的三款基于Wat

IBM Watson将“狙击”癌症、糖尿病、眼疾、脑疾及心脏病等重大疾病

IBM日前宣布,公司已成立了IBM Watson Health医学影像协作计划,这是一项全球协作,共由超过15家著名的卫生机构、学院医疗中心、影像诊断供应商和医学影像技术公司组成,旨在将认知影像技术应用到医疗机构的日常工作中,帮助医生诊断乳腺癌、肺癌及其他癌症,以及糖尿病、眼疾、脑疾、心脏病及其相关病症,如中风。协作计划的成员使用IBM Watson从以前“看不见的”非结构化影像数据中提取洞察,并